ニュース

Tokyo, April 11, 2025 — Dr. Reddy’s Laboratories’ Active Pharmaceutical Ingredients (API) division made a strong impression at CPHI Japan 2025, held at Tokyo Big Sight from April 9–11. As one of the leading global suppliers of high-quality APIs, the company highlighted its expansive portfolio of over 250 APIs across key therapeutic areas including oncology, cardiovascular, and dermatology. The team, led by Nirav Shah, Vice President and Head of API – North Asia, engaged with partners and stakeholders to discuss sustainable sourcing, regulatory excellence, and early market entry strategies. Dr. Reddy’s also emphasized its commitment to sustainability and ESG leadership, having earned recognition in the Bloomberg Gender-Equality Index and Dow Jones Sustainability Index.